New research indicates that patients who come off popular slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Research printed in a prominent health publication shows that while obese people can lose a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such medications must be informed of the risk of quick weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of recovery means a reversion to pre-treatment mass within about 18 months.
Weighing Treatments
The research, which looked at dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with older methods.
Scientists point out that individuals who shed pounds through lifestyle changes alone generally have a slower creep back—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Nutrition scientists suggest the mode of action of the drugs explains the heightened regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels several times higher than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making binge eating far more likely."
An Ongoing Condition?
Medical guidelines advise the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Professionals contend that, due to the likelihood of weight regain, the treatment is often long-term.
This opinion is echoed by drug manufacturers, who note that the results "emphasize the long-term character of excess weight," akin to managing conditions like high blood pressure.
Patient Accounts
Users who have come off the medication report a powerful return of cravings.
"I experienced a switch that goes on and I was suddenly starving," said a patient.
This difficulty is worsened if individuals have not developed permanent lifestyle or habit modifications during treatment.
Growing Adoption
Survey data suggest that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is more common among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians emphasize that while these medications are potent tools for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing behavioural management.
